ST Germain D J Co. Inc. Trims Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

ST Germain D J Co. Inc. trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 90,845 shares of the medical equipment provider's stock after selling 4,885 shares during the period. ST Germain D J Co. Inc.'s holdings in Zimmer Biomet were worth $9,596,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. BLB&B Advisors LLC boosted its holdings in Zimmer Biomet by 2.1% in the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider's stock worth $529,000 after buying an additional 100 shares during the period. FWG Holdings LLC boosted its holdings in shares of Zimmer Biomet by 2.9% in the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider's stock worth $372,000 after acquiring an additional 101 shares during the period. Financial Advocates Investment Management boosted its holdings in shares of Zimmer Biomet by 3.5% in the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider's stock worth $330,000 after acquiring an additional 103 shares during the period. M&R Capital Management Inc. raised its stake in shares of Zimmer Biomet by 14.1% during the 3rd quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider's stock valued at $92,000 after purchasing an additional 105 shares during the period. Finally, Mill Creek Capital Advisors LLC raised its stake in shares of Zimmer Biomet by 5.1% during the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider's stock valued at $238,000 after purchasing an additional 106 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Up 2.9 %

Shares of ZBH traded up $2.93 during trading hours on Friday, hitting $104.47. The company had a trading volume of 2,709,275 shares, compared to its average volume of 1,769,996. The firm has a market cap of $20.80 billion, a P/E ratio of 19.86, a P/E/G ratio of 1.96 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $100.67 and a 52-week high of $133.90. The stock's 50 day moving average price is $108.03 and its 200 day moving average price is $108.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the previous year, the company posted $1.65 earnings per share. The business's revenue was up 4.1% on a year-over-year basis. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date is Monday, December 30th. Zimmer Biomet's payout ratio is 18.25%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Wells Fargo & Company lifted their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an "equal weight" rating in a report on Thursday, October 31st. BTIG Research cut their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating for the company in a report on Thursday, October 3rd. Royal Bank of Canada upped their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday, November 4th. Raymond James dropped their price objective on Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. Finally, Truist Financial upped their target price on Zimmer Biomet from $117.00 to $118.00 and gave the stock a "hold" rating in a research note on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $123.33.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.